Published in AIDS Weekly, March 11th, 2002
Under the terms of the agreement, Achillion can utilize ViroLogic's assays to evaluate its pipeline of investigational antiviral agents.
Achillion is currently evaluating Beta-L-Fd4C in chronically nfected HBV patients in a phase Ib/II clinical trial. Additional phase II studies are planned for 2002 to evaluate the drug in both chronic HBV and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.